These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 27357286

  • 21. CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease.
    Hu WT, Watts KD, Tailor P, Nguyen TP, Howell JC, Lee RC, Seyfried NT, Gearing M, Hales CM, Levey AI, Lah JJ, Lee EK, Alzheimer’s Disease Neuro-Imaging Initiative.
    Acta Neuropathol Commun; 2016 Feb 17; 4():14. PubMed ID: 26887322
    [Abstract] [Full Text] [Related]

  • 22. APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease.
    Wang S, Zhang J, Pan T, for Alzheimer’s Disease Neuroimaging Initiative.
    Neurosci Lett; 2018 Oct 15; 685():109-113. PubMed ID: 30144541
    [Abstract] [Full Text] [Related]

  • 23. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.
    Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, Laitinen M, Remes AM, Koivisto AM, Mattila KM, Lehtimäki T, Verhey FR, Visser PJ, Soininen H, Hiltunen M.
    PLoS One; 2013 Oct 15; 8(4):e59676. PubMed ID: 23573206
    [Abstract] [Full Text] [Related]

  • 24. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
    Wattmo C, Blennow K, Hansson O.
    BMC Neurol; 2020 Jan 09; 20(1):10. PubMed ID: 31918679
    [Abstract] [Full Text] [Related]

  • 25. Association of oxidative stress and inflammatory metabolites with Alzheimer's disease cerebrospinal fluid biomarkers in mild cognitive impairment.
    Ahmad S, Yang W, Orellana A, Frölich L, de Rojas I, Cano A, Boada M, Hernández I, Hausner L, Harms AC, Bakker MHM, Cabrera-Socorro A, Amin N, Ramírez A, Ruiz A, Van Duijn CM, Hankemeier T.
    Alzheimers Res Ther; 2024 Jul 30; 16(1):171. PubMed ID: 39080778
    [Abstract] [Full Text] [Related]

  • 26. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K.
    Neurosci Lett; 2008 Aug 01; 440(2):145-9. PubMed ID: 18555606
    [Abstract] [Full Text] [Related]

  • 27. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
    Lautner R, Insel PS, Skillbäck T, Olsson B, Landén M, Frisoni GB, Herukka SK, Hampel H, Wallin A, Minthon L, Hansson O, Blennow K, Mattsson N, Zetterberg H.
    Alzheimers Res Ther; 2017 Oct 23; 9(1):87. PubMed ID: 29061195
    [Abstract] [Full Text] [Related]

  • 28. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease.
    Wang L, Gao T, Cai T, Li K, Zheng P, Liu J, Alzheimer’s Disease Neuroimaging Initiative.
    Neurosci Lett; 2020 Jan 10; 715():134658. PubMed ID: 31794792
    [Abstract] [Full Text] [Related]

  • 29. Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer's disease: racial differences.
    Xu C, Xiao D, Su BB, Saveron JM, Gamez D, Navia RO, Wang N, Roy U, Adjeroh DA, Wang K, Alzheimer and Disease Neuroimaging Initiative.
    Neurol Sci; 2024 Mar 10; 45(3):1041-1050. PubMed ID: 37759100
    [Abstract] [Full Text] [Related]

  • 30. Exploring the effect of APOE ε4 on biomarkers of neurodegeneration in Alzheimer's disease.
    Agnello L, Gambino CM, Ciaccio AM, Piccoli T, Blandino V, Scazzone C, Lo Sasso B, Del Ben F, Ciaccio M.
    Clin Chim Acta; 2024 Aug 15; 562():119876. PubMed ID: 39025198
    [Abstract] [Full Text] [Related]

  • 31. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
    Gabriel AJ, Almeida MR, Ribeiro MH, Durães J, Tábuas-Pereira M, Pinheiro AC, Pascoal R, Santana I, Baldeiras I.
    Neurosci Lett; 2017 Feb 22; 641():101-106. PubMed ID: 28108398
    [Abstract] [Full Text] [Related]

  • 32. Association of APOE-ε4 and GAP-43-related presynaptic loss with β-amyloid, tau, neurodegeneration, and cognitive decline.
    Lan G, Du J, Chen X, Wang Q, Alzheimer’s Disease Neuroimaging Initiative, Han Y, Guo T.
    Neurobiol Aging; 2023 Dec 22; 132():209-219. PubMed ID: 37852045
    [Abstract] [Full Text] [Related]

  • 33. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
    Saddiki H, Fayosse A, Cognat E, Sabia S, Engelborghs S, Wallon D, Alexopoulos P, Blennow K, Zetterberg H, Parnetti L, Zerr I, Hermann P, Gabelle A, Boada M, Orellana A, de Rojas I, Lilamand M, Bjerke M, Van Broeckhoven C, Farotti L, Salvadori N, Diehl-Schmid J, Grimmer T, Hourregue C, Dugravot A, Nicolas G, Laplanche JL, Lehmann S, Bouaziz-Amar E, Alzheimer’s Disease Neuroimaging Initiative, Hugon J, Tzourio C, Singh-Manoux A, Paquet C, Dumurgier J.
    PLoS Med; 2020 Aug 22; 17(8):e1003289. PubMed ID: 32817639
    [Abstract] [Full Text] [Related]

  • 34. Association of complement factor H Y402H gene polymorphism with Alzheimer's disease.
    Zetterberg M, Landgren S, Andersson ME, Palmér MS, Gustafson DR, Skoog I, Minthon L, Thelle DS, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zetterberg H.
    Am J Med Genet B Neuropsychiatr Genet; 2008 Sep 05; 147B(6):720-6. PubMed ID: 18163432
    [Abstract] [Full Text] [Related]

  • 35. The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers.
    Benitez BA, Karch CM, Cai Y, Jin SC, Cooper B, Carrell D, Bertelsen S, Chibnik L, Schneider JA, Bennett DA, Alzheimer's Disease Neuroimaging Initiative, Genetic and Environmental Risk for Alzheimer's Disease Consortium GERAD, Fagan AM, Holtzman D, Morris JC, Goate AM, Cruchaga C.
    PLoS Genet; 2013 Sep 05; 9(8):e1003685. PubMed ID: 23990795
    [Abstract] [Full Text] [Related]

  • 36. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.
    Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW, Alzheimer's Disease Neuroimaging Initiative.
    Neurobiol Aging; 2010 Aug 05; 31(8):1340-54. PubMed ID: 20570401
    [Abstract] [Full Text] [Related]

  • 37. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease.
    Konijnenberg E, Tijms BM, Gobom J, Dobricic V, Bos I, Vos S, Tsolaki M, Verhey F, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, Frölich L, Lovestone S, Streffer J, Bertram L, Blennow K, Teunissen CE, Veerhuis R, Smit AB, Scheltens P, Zetterberg H, Visser PJ.
    Alzheimers Res Ther; 2020 May 27; 12(1):65. PubMed ID: 32460813
    [Abstract] [Full Text] [Related]

  • 38. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM.
    Acta Neuropathol; 2014 May 27; 127(5):633-43. PubMed ID: 24633805
    [Abstract] [Full Text] [Related]

  • 39. Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease.
    Ott BR, Cohen RA, Gongvatana A, Okonkwo OC, Johanson CE, Stopa EG, Donahue JE, Silverberg GD, Alzheimer's Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2010 May 27; 20(2):647-57. PubMed ID: 20182051
    [Abstract] [Full Text] [Related]

  • 40. Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.
    Osorio RS, Ayappa I, Mantua J, Gumb T, Varga A, Mooney AM, Burschtin OE, Taxin Z, During E, Spector N, Biagioni M, Pirraglia E, Lau H, Zetterberg H, Blennow K, Lu SE, Mosconi L, Glodzik L, Rapoport DM, de Leon MJ.
    Neurobiol Aging; 2014 Jun 27; 35(6):1318-24. PubMed ID: 24439479
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.